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ABSTRACT: Most immunomodulatory materials (e.g., vaccine
adjuvants such as alum) modulate adaptive immunity, and yet
little eﬀort has focused on developing materials to regulate innate
immunity, which get mentioned only when inﬂammation aﬀects
the biocompatibility of biomaterials. Traditionally considered as
short-lived eﬀector cells from innate immunity primarily for the
clearance of invading microorganisms without speciﬁcity,
neutrophils exhibit a key role in launching and shaping the
immune response. Here we show that the incorporation of
unnatural amino acids into a well-known chemoattractantN-
formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF)oﬀers a facile approach to create a de novo, multifunctional
chemoattractant that self-assembles to form supramolecular nanoﬁbrils and hydrogels. This de novo chemoattractant not only
exhibits preserved cross-species chemoattractant activity to human and murine neutrophils, but also eﬀectively resists proteolysis.
Thus, its hydrogel, in vivo, releases the chemoattractant and attracts neutrophils to the desired location in a sustainable manner.
As a novel and general approach to generate a new class of biomaterials for modulating innate immunity, this work oﬀers a
prolonged acute inﬂammation model for developing various new applications.
Upon the breach of the host physical barrier by intrudingmicroorganisms, neutrophils, among all the leukocytes,
are the ﬁrst to inﬂux into focus for bacterial invasion for host
defense.1 Neutrophils used to be considered to function
exclusively as the eﬀector cells in the innate phase of immune
response. However, the old view has been challenged since a
growing body of evidence has shown that neutrophils play a
crucial role in framing immune response, both innate and
adaptive immunity.2 For example, neutrophils are found to have
a B cell-helper neutrophil population in the splenic marginal
zone, and these neutrophils can activate marginal zone B cells
to secrete immunoglobulins against T cell-independent
antigens.3
The eﬃcient recruitment of neutrophils depends on many
signals, including N-formyl peptides, chemokines, complement
components, and leukotrienes.1 As byproducts of protein
translation in the invading bacteria, N-formyl peptides form
molecular gradients originating from the bacteria in the infected
tissue, and the gradients of N-formyl peptides signal
neutrophils to migrate (i.e., chemotaxis) toward their targets
while overriding other minor signals, such as IL-8 and MIP-2.1
Proposed in 1965 and conﬁrmed in 1984, fMLF represents the
best-known N-formyl peptide and one of the most well-
established chemoattractants for neutrophils (Figure 1).4
Having a well-deﬁned molecular structure, fMLF oﬀers an
opportunity for chemical modiﬁcations and for precise control
and accurate understanding of immunomodulation at the
molecular level. Recognized for its potential as a useful reagent
to induce acute inﬂammation in vivo, fMLF, in the form of
aqueous solution, has been injected subcutaneously,5 intra-
venously,6 intraplantarly,7 intradermally,8 or just topically
applied on the microvasculature9 to study the biology of
neutrophils for various applications. Although the aqueous
solution of fMLF is able to induce the accumulation of
neutrophils, its eﬀect is relatively weak and transient (2−6 h).10
Instead of weak and transient acute inﬂammation, sometimes
reagents that can elicit inﬂammation for a longer period are
highly desired. However, the ﬁeld of biomaterials concerning
neutrophils and inﬂammation has been focused on suppressing
inﬂammation as the foreign body response to biomaterials.11
Most recently, material scientists have started to pay attention
to regulation of innate immunity and neutrophils, still focus on
inﬂammation imaging12 and suppression.13 Demonstrated in a
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recent work, the intratumoral injection of fMLF solution every
2 days after the inoculation of tumor cells slows tumor growth
in a xenograft tumor model.14 Similarly, the daily intratumoral
injection of another chemoattractant, chemerin, decreases the
tumor growth.15 In order to maintain a meaningful local
concentration of chemoattractants, both studies required
frequent intratumoral injections.14,15 Therefore, a formulation
of chemoattractant (e.g., fMLF) for prolonged release not only
acts as a useful tool to study the biology of neutrophils over
long duration, but also holds promise for therapeutic
applications, like cancer treatment. This potential has already
led to the exploration of diﬀerent formulations of fMLF,16−18
such as particles of fMLF in suspensions produced by
sonication for studying neutrophil inﬁltration into pulmonary
alveoli during murine pneumococcal pneumonia,16 physically
encapsulated N-formyl peptides in poly(lactic-co-glycolic acid)
(PLGA) microbeads for inducing chemotaxis of neutrophils,17
or human monocytes and monocyte-derived dendritic cells
(DCs)18 in vitro. Based on the same idea of physical
encapsulation by polymers, chemoattraction of regulatory T
cells in vivo has been achieved by releasing CCL22 from PLGA
particles.19 Despite this progress, heterogeneous suspensions of
fMLF particles are far from ideal for in vivo applications due to
diﬀerences between batches, and physical encapsulation using
polymeric materials suﬀers from several limitations, such as
burst release, low capacity for payload, and slow bioresorption
of the polymeric materials, along with its inherent problem as
mixtures of molecules with diﬀerent molecular weight. These
limitations demand the development of new approaches to
attract neutrophils in vivo.
As an alternative, learning from nature, we chose to develop a
biomimetic approach for sustained release of fMLF in vivo.
Away from the dominant drug delivery idea of drug loading
onto vehicles, such as biodegradable polymers, nature has
provided a strategy, of which natural peptides and proteins self-
assemble to form functional amyloids for sustained release.20
Certain hormones such as prolactin and growth hormone form
Figure 1. Illustration of conversion of fMLF to an fMLF-based
hydrogelator (3) to induce chemotaxis of neutrophils in vitro and
accumulation of neutrophils in vivo. In vitro assay: 3 induces
chemotaxis of murine and human neutrophils at the minimum
eﬀective concentrations of 1.13 μM and 11.3 nM, respectively. In vivo
assay: the hydrogel of 3 slowly releases 3 for attracting neutrophils to
the location of the hydrogel (at the dosage of 0.935 μmol per mouse).
Notation: f = formyl, M = L-methionyl residue, L = L-leucyl residue, F
= L-phenylalaninyl residue, 2-Nal = L-3-(2-naphthyl)-alaninyl residue
and D-2-Nal = D-3-(2-naphthyl)-alaninyl residue.
Figure 2. Characterization of fMLF-derived hydrogelators (1, 2, 3) and a control peptide (4) and the hydrogels. (A−D) Typical TEM images of
negatively stained ﬁbrils of (A) the hydrogels of 1 (0.20 w/v%), (B) 2 (0.40 w/v%), (C) 3 (0.125 w/v%), and (D) 4 (0.075 w/v%), respectively,
with the molecular representation on top (all hydrogels are at pH = 7.4 in DPBS buﬀer; the scale bar is 100 nm; notation: Ac = acetyl; inset: the
optical images of the hydrogels). (E) Strain sweep and (F) frequency sweep of the hydrogels with the same concentrations as the hydrogels prepared
for optical images and TEM. (G) Digestion of 1, 2, and 3, respectively, in a 3.5 mL HEPES buﬀer solution of 1.4 mg (0.4 mg/mL) by adding 2.8 μL
of proteinase K solution at 37 °C. (H) Release proﬁles of the monomers from the hydrogels of 1, 2, 3, and 4 (0.4 w/v%) at 37 °C.
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amyloids for storage, which dissolve slowly as a way for
sustained or regulated hormone secretion.21 This principle and
mechanism have led to the development of supramolecular
nanoﬁbrils and hydrogels22 of bioactive molecules as “self-
delivery drugs”.20 In fact, a hydrogel of lanreotide acetate (i.e.,
Somatuline Depot),23 based on this mechanism, has found
clinical application for treating acromegaly. This success has
stimulated the development of supramolecular hydrogels as a
unique depot for controlled release.20,23−25 However, existing
examples of using self-assembly of peptides as a releasing depot
have almost all been discovered by accident. The self-assembly
property was not included in the molecular design of the small
molecular drug, which was discovered afterward. However, the
real challenge for a “releasing depot” is how to modify existing
bioactive molecules into derivatives with preserved bioactivity
while gaining the new function of self-assembly into nanoﬁbrils.
Intrigued by the simplicity and eﬀectiveness of the “self-delivery
drugs”, also from the perspective of peptide engineering and
peptide formulation, we hypothesized that, by rational chemical
derivatization, fMLF-derived peptides would form supra-
molecular hydrogels without compromising the biological
eﬃcacy of fMLF, and the corresponding hydrogels would
deliver long-term eﬃcacy for local accumulation of neutrophils
by sustained release of the chemotactic hydrogelators (Figure
1).
To demonstrate the concept illustrated in Figure 1, we
designed, synthesized, and evaluated several fMLF-derived
molecules; and we obtained N-formyl-L-methionyl-L-leucyl-L-3-
(2-naphthyl)-alaninyl-D-3-(2-naphthyl)-alanine (i.e., fMet-Leu-
(2-Nal)-(D-2-Nal) shown as 3 in Figure 1). In addition to
behaving as a hydrogelator, 3 exhibits three advantageous
features: ability to form a hydrogel eﬃciently (minimum
gelation concentration (MGC) = 0.125% w/v in DPBS buﬀer),
enhanced stability against proteolysis, and preserved activity to
both mouse and human neutrophils. Moreover, the hydrogel of
3, in the murine peritonitis model, stimulates a much longer-
lasting pro-inﬂammatory phase than fMLF solution does, and
exhibits a 2 orders of magnitude increase in neutrophil
accumulation compared to that of fMLF solution. This work,
for the ﬁrst time, not only oﬀers a facile approach to convert
chemoattractants into hydrogels with exceptional biostability
and tailored activity for controlled accumulation of neutrophils
in vivo, but also validates the concept of the supramolecular
hydrogelators acting as chemoattractants for homing cells in a
sustainable manner. Besides being a useful tool to study the
biology of innate immunity, this prolonged inﬂammation model
holds promise for various potential therapeutic applications26
(e.g., inhibiting tumor growth,14,15 decreasing mortality caused
by lethal sepsis after microbial infection,27 and acting as a basis
for vaccine adjuvants28). Furthermore, the same principle can
apply to the design of molecular hydrogels of formyl peptide
receptor (FPR) antagonists, which ﬁnds direct applications in
controlling pain caused by microbial infection.29
Figure 2 shows the schematic representation of the fMLF-
derived peptides that self-assemble in water and form hydrogels
and their characterizations (e.g., TEM, rheological properties,
proteolytic stability, and the release proﬁles). The chemical
structures are shown in Supporting Information Figure S1.
Based on the structure of fMLF, we mainly modiﬁed fMLF at
the C-terminus.30 Since the naphthyl group promotes
formation of hydrogels from small peptides,23,24 we connected
an unnatural amino acid with a naphthyl group (2-Nal) to
fMLF to obtain fMLF-(2-Nal) (1). 1 self-assembles in
Dulbecco’s Phosphate-Buﬀered Saline (DPBS) buﬀer to form
a supramolecular hydrogel at a concentration of 0.2 w/v%
(Figure 2A, inset). Transmission electron microscopy (TEM)
reveals the network of nanoﬁbrils (around 16 nm in diameter)
(Figure 2A) in the hydrogel of 1 (0.2 w/v%), which shows
storage modulus (G′) of around 50 Pa and critical strain of
about 10.0% (Figure 2E,F). As shown in Figure 2G, incubation
with a powerful protease (e.g., proteinase K) causes more than
90% of 1 to undergo hydrolysis in the ﬁrst 2 h. The release of 1
from its hydrogel ﬁnishes in about 8 h (Figure 2H).
To improve the stability of the hydrogelator against
proteolytic enzymes, we replaced the fourth L-amino acid
residue to the corresponding D-amino acid residue31 to obtain a
new peptide, fMLF-(D-2-Nal) (2), which still forms a hydrogel
(Figure 2B, inset) but at a higher concentration (MGC: 0.4 w/
v%) than that of 1. As shown in the TEM images, the
nanoﬁbrils in the hydrogel of 2 have diameters around 22 nm
(Figure 2B). Rheology measurement shows the storage
modulus and the critical strain of the hydrogel of 2 to be
around 200 Pa and about 1.0%, respectively (Figure 2E,F). The
incorporation of a D-amino acid, indeed, substantially enhances
proteolytic stability of 2 in comparison with that of 1. For
example, in the presence of proteinase K, more than 80% and
40% of 2 remains after 2 h and after 12 h, respectively (Figure
2G). The hydrogel of 2 collapses within the ﬁrst 4 h and
completely dissolves after 6 h in DPBS buﬀer at 37 °C (Figure
2H), suggesting the relatively loose molecular packing in the
hydrogel of 2.
Therefore, to obtain an fMLF derivative that has better
gelation properties, we changed the third amino acid residue on
2 from Phe to 2-Nal, which gave the peptide fML-(2-Nal)-(D-
2-Nal) (3). This simple change boosts the intermolecular
aromatic−aromatic interaction that promotes molecular self-
assembly in water for hydrogelation, so 3 exhibits excellent
gelation properties with an MGC of 0.125 w/v% (Figure 2C,
inset). The hydrogel prepared at the concentration of 0.125 w/
v% has nanoﬁbrils with diameters around 18 nm (Figure 2C),
storage modulus around 100 Pa, and critical strain around 2.0%
(Figure 2E,F). Not only does 3 maintain resistance to the
proteinase K proteolysis (Figure 2G), but the improved
gelation property also results in a longer sustained release of
3 in vitro. The stability of 3 is much higher than that of fMLF
itself.32 The hydrogel of 3 releases about 60% of 3 after 24 h
incubation at 37 °C (Figure 2H).
The importance of the formyl group for the activity of the N-
formyl peptides has been well documented, and the
replacement of the formyl group by the acetyl group in fMLF
causes a 1000 to 10 000 fold activity drop.33 Therefore, we also
synthesized a control molecule of 3, AcML-(2-Nal)-(D-2-Nal)
(4). It forms a hydrogel (Figure 2D, inset) at a low
concentration (MGC = 0.075 w/v%). The hydrogel of 4
contains nanoﬁbrils with diameters around 17 nm (Figure 2D)
and has a storage modulus around 140 Pa and a critical strain
around 2.0% (Figure 2E,F). 4 is less stable against proteolytic
digestion by proteinase K than 3. Matching with its excellent
gelation property, the hydrogel of 4 also gradually releases 4
(with 40% release at the ﬁrst 24 h) (Figure 2H).
These four hydrogels, prepared at the MGCs of the
hydrogelators, exhibit comparable storage moduli (G′), loss
moduli (G″), and critical strains (Figure 2E,F). Together with
the facts that the moduli of these hydrogels depend little on the
frequency and the nanoﬁbrils serving as the matrices of the
hydrogels have close diameters (16−22 nm), these results
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suggest that the hydrogels of fMLF-based molecules share
similar morphological and rheological properties. In addition,
the MGC values of the hydrogelators correlate well with the
release proﬁles of the hydrogelators. For example, the order of
the hydrogelators having MGCs from high to low is 2, 1, 3, and
4, which is the same as the order of the hydrogelator release
rates (Figure 2H). This trend suggests that molecular
engineering of the hydrogelators to control the MGC values
should be eﬀective and useful for tailoring the release proﬁles of
the chemoattractants.
After conﬁrming that the fMLF derivatives act as hydro-
gelators and exhibit proteolytic stability, we determined their
activity to murine neutrophils by measuring chemotaxis and
ROS production. Figure 3A shows the frames of the chemotaxis
(performed on the EZ-TAXIScan34) induced by diﬀerent
molecules at 0, 5, and 10 min to determine the minimum
eﬀective concentrations of the fMLF derivatives. The recorded
frames of the ﬁrst 20 min serve as traces of cell migration
(Figure 3B), which, being analyzed by the algorithm shown in
Figure 3C, provide three important parameters for neutrophil
chemotaxis: migration speed (Figure 3D), directionality (0 to
1) (Figure 3E), and upward directionality (−1 to 1) (Figure
3F) to characterize, respectively, how fast the neutrophils move,
how straight they migrate, and how faithfully they follow the
gradients of the chemoattractants. Chemoattractants also
induce the production of reactive oxygen species (ROS) by
the NADPH oxidase assembled on the plasma membrane and
phagosome.1 Thereby, the quantiﬁcation of ROS production
using isoluminol also indicates the activity of the chemo-
attractants. According to Figure 3A−G, at its minimum
eﬀective concentration (1.13 μM), which is about 1000 times
lower than the minimum gelation concentration, 3 not only
induces chemotaxis of murine neutrophils as eﬀectively as
fMLF (i.e., the almost identical migration speed (Figure 3D)
and directionality (Figure 3E), and slightly better upward
directionality (Figure 3F)), but also exhibits slightly more
potent activity for generation of ROS than that of fMLF
(Figure 3G). The reason for the faster ROS production
activated by 3 is currently unknown, which might be related to
its interaction with formyl peptide receptors (FPRs).
Interestingly, 1, at 113 nM, exhibits similar chemotactic
activities as that of fMLF at 1.13 μM (Figure 3A), but
generates only half as much ROS as fMLF (Figure 3G). 2
exhibits drops in the chemotactic activity and the ROS
production when compared with fMLF, which matches the
previously reported results that the D enantiomer is a less active
chemoattractant than the L enantiomer.35 4 failed to induced
the chemotaxis even at 113 μM, 100 fold of the minimum
eﬀective concentration of 3 (Supporting Information Figure
S2), which matches the 1000 to 10 000 fold activity drop
Figure 3. Induction of chemotaxis and ROS production of murine neutrophils by fMLF-derived hydrogelators (1, 2, and 3) in vitro. (A) Snapshots
of chemotaxis of murine neutrophils at 0, 5, and 10 min induced by the gradient of fMLF; 1, 2, and 3 performed on EZ-TAXIScan,34 with the blank
control. (B) Traces of 20 typical migrating neutrophils corresponding to diﬀerent chemoattractants in the ﬁrst 20 min. (C) Scheme and formulas for
the calculation of the migration parameters. (D) Migration speed, (E) directionality, and (F) upward directionality of the murine neutrophils during
chemotaxis from three independent samples, and each sample has 20 cell traces. (G) ROS production in the neutrophils (5 × 105) after stimulation
with DMSO (0.1 v/v%, as the negative control), fMLF (10 μM), 1 (1 μM), 2 (10 μM), and 3 (10 μM).
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reported in the literature.33 Therefore, 4 is considered to have
no chemotactic activity, and the hydrogel of 4 can be used as a
control for the hydrogel of 3.
These results clearly show that 3 fulﬁlls all three criteria of
the molecular design: excellent gelation property for the
purpose of sustained release, fair stability against proteolysis,
and well preserved chemotactic activity to murine neutrophils.
Encouraged by the in vitro activity of 3 to attract murine
neutrophils, we also investigated the activity of 3 on human
neutrophils. As shown in Figure 4A, the minimum eﬀective
concentration of fMLF to human neutrophils is 11.3 nM
determined by a 10-fold serial dilution, which is 100 times
lower than the minimum eﬀective concentration of fMLF to
murine neutrophils (1.13 μM). This result agrees with the
Figure 4. Induction of chemotaxis and ROS production of human neutrophils by 3 in vitro. (A) Snapshots of chemotaxis of puriﬁed neutrophils
from healthy human donors at 0, 5, and 10 min induced by fMLF, 3, and PBS (as the control) performed on EZ-TAXIScan. (B) Traces of 20 typical
migrating neutrophils corresponding to diﬀerent chemoattractants. (C) Migration speed, (D) directionality, and (E) upward directionality of the
human neutrophils during chemotaxis from three independent samples, and each sample has 20 cell migration traces. (F) ROS production in the
neutrophils (5 × 105) after the addition of fMLF (100 nM), 3 (100 nM), and PBS (as the blank control).
Figure 5. Hydrogels stimulate prolonged accumulation of murine neutrophils in vivo. (A) Representative ﬂow cytometry plots showing the
neutrophils (Gr1+CD11b+) and the monocytes and macrophages (Gr1−CD11b+) from the cells collected from the peritoneal lavage of wild-type
mice 24 h after receiving the intraperitoneal injections (IP injections) of 500 μL of PBS (as the control), the solution of fMLF, and the hydrogels of
1, 3, and 4 containing 0.935 μmol of peptides. (B) The number of neutrophils and (C) the ratio of the number of neutrophils vs the number of
macrophages according to the FACS quantiﬁcation from three independent experiments.
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observation that fMLF’s activity to murine FPR is 100 to 10
000 fold less than to human and rabbit FPRs.36 Moreover, 3, at
11.3 nM, exhibits the same eﬀectiveness as fMLF to human
neutrophils, as evidenced by the indistinguishable migration
traces (Figure 4B), similar migration parameters (Figure
4C,D,E), and essentially identical ROS production (Figure
4F). Although the binding pockets of the mouse and human
FPRs might be quite diﬀerent, which is suggested by fMLF’s
signiﬁcantly diﬀerent activity to FPRs,36 the well preserved
chemotactic activity of 3 to both mouse and human neutrophils
indicates that 3 maintains binding to both human and murine
FPRs. How the modiﬁcation can satisfy the binding to the two
seemingly quite diﬀerent pockets is surprisingly interesting and
certainly deserves further exploration.
After successfully demonstrating the in vitro properties (i.e.,
gelation property for sustained release, stability, and the
chemotactic activity to both mouse and human neutrophils)
of 3, we used an in vivo murine model to determine whether
the hydrogel of 3 achieves a longer proinﬂammatory eﬀect for
attracting neutrophils than the solution of fMLF. We collected
peritoneal lavages for ﬂow cytometry 24 h after the injection of
DPBS solution, fMLF solution, and the gels of 1, 3, and 4 into
mice, respectively. In the representative ﬂow cytometry plots
(Figure 5A) using the markers Gr1 and CD11b, the double
positive (Gr1+CD11b+) corresponds to neutrophils and the
Gr1−CD11b+ are monocytes macrophages. The acute inﬂam-
mation starts with the rapid inﬂux of neutrophils and switches
to monocyte-derived inﬂammatory macrophages, both from the
blood. Although it is not clear cut, the initial inﬂux with a high
percentage of neutrophils is considered the pro-inﬂammatory
phase and the later stage with dominant macrophages is the
resolution phase. Therefore, the ratio of neutrophils to
macrophages is the indicator of the inﬂammation phase.37 As
shown in Figure 5A, while the eﬀect of the solution of fMLF
almost disappears 24 h after the injection, the hydrogel of 3,
having the same amount of N-formyl peptides as the fMLF
solution, still attracts high counts of neutrophils. According to
the quantiﬁcation (Figure 5B), the neutrophil number attracted
by the hydrogel of 3 is 2 orders of magnitude higher than that
of the solution of fMLF. Moreover, the ratio of the number of
neutrophils vs the number of macrophages (Figure 5C)
suggests that the inﬂammation of the peritoneum (peritonitis)
induced by the hydrogel of 3 is in a much earlier phase than the
solution of fMLF, which is in the resolution phase of the
inﬂammation. Although the hydrogel of 4 also results in
stronger accumulation of neutrophils than the solution of fMLF
does, the total number of neutrophils is still 1 order of
magnitude lower than that induced by the hydrogel of 3
(Figure 5B). In addition, the ratio of neutrophils to
macrophages (Figure 5C) clearly shows that the inﬂammation
induced by the hydrogel of 4 is also close to the resolution
phase. These results agree with the chemotactic activity of the
hydrogelators 3 and 4, and suggest the accumulation of
neutrophils caused by the hydrogel of 4 probably due to the
inﬂammatory response toward stable foreign materials.
As the other control, the hydrogel of 1 results in similar
results as the solution of fMLF: low total number of neutrophils
and low ratio of neutrophils to macrophages 24 h after the
injections (Figure 5B and C). Although 1 is roughly 10 times
more chemotactically active than 3 (Figure 3), the hydrogel of
1 releases more rapidly than the hydrogel of 3, and 1 is less
stable than 3. Therefore, the stronger accumulation of
neutrophils induced by the hydrogel of 3 than by the hydrogel
of 1 likely not only is due to the inﬂammatory response to
stable foreign materials (as the case of the hydrogel of 4), but
also originates from the sustained release of more stable
chemoattractive hydrogelators. This result suggests that it is
feasible to modulate inﬂammation by controlling the
rheological properties of the hydrogels, the release proﬁles,
and the stabilities of the hydrogelators.
Because neutrophils, as short-lived cells,1 have a half-life of
1.5 h in the circulation in mice, the accumulation of neutrophils
in this murine model is diﬀerent from the other cell
accumulations where the attracted cells remain alive. Therefore,
the results, shown in Figure 5, could not be interpreted as the
explosive accumulation of neutrophils induced in the ﬁrst
couple of hours all at once and then no activity to follow.
Instead, the results from 24 h strongly support that the
accumulation of neutrophils is due to a constant attraction by
the sustained release of the hydrogelators from the hydrogel of
3.
Forty-eight hours after injections (Supporting Information
Figure S3), the number of neutrophils attracted by the hydrogel
of 3 is 1.1 ± 0.3 × 104 and the ratio of neutrophils to
macrophages is 0.05 ± 0.03, which shows that the peritonitis
induced by the hydrogel of 3 also moves into the resolution
phase, suggesting that the controlled release exhausts between
24 and 48 h. This might be related to the watery environment
of the peritoneum due to peritoneal ﬂuid.
In summary, this study illustrates the evolution of multi-
functional molecular hydrogelators for attracting neutrophils in
vitro and in vivo. As the new class of “self-delivery”
biomaterials, supramolecular hydrogels are only in their infancy
for immunomodulation, with some initial but exciting
exploration on vaccines for adaptive immunity.38 Our work is
the ﬁrst example of using molecular self-assembly for the
construction of immunomodulatory materials for innate
immunity. The self-assembled hydrogel of fMLF-derived
peptides, as a unique tool, can be very useful to researchers
who need to induce sustained innate immune recruitment,
which had been unavailable before. Furthermore, this hydrogel
also holds therapeutic potential that has yet to be explored.
More broadly, besides fMLF, there are many small biological
peptides, playing essential roles in diverse biological functions.
However, our preliminary study on the attracting neutrophils to
the tumor sites on a B16−F10 melanoma model indicates that
the peritumoral injection of the gel of 3 or the solution of fMLF
gas has little eﬀect on the growth of the tumor in rat. This
result suggests more extensive study on this observation is
needed. The concept illustrated in this work along with other
work shows the potential to modify those peptides to form
supramolecular hydrogels without compromising the bioactiv-
ity,39 and the insight of molecular design gained from this work
can be very useful for the further development of
immunomodulating hydrogels. The general concept of using
supramolecular hydrogel of bioactive small molecules as a “self-
delivery” system, thus, provides a novel approach to
therapeutics and an attractive and validated alternative to the
traditional drug delivery system.
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